1.Small interfering RNA (siRNA): a hope for the loss-of-function studies in anesthesiology?.
Korean Journal of Anesthesiology 2010;59(6):369-370
No abstract available.
RNA, Small Interfering
2.siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens.
Nitin Kumar SINGH ; Bo Yeun SEO ; Mathukumalli VIDYASAGAR ; Michael A WHITE ; Hyun Seok KIM
Genomics & Informatics 2013;11(1):55-57
Growing numbers of studies employ cell line-based systematic short interfering RNA (siRNA) screens to study gene functions and to identify drug targets. As multiple sources of variations that are unique to siRNA screens exist, there is a growing demand for a computational tool that generates normalized values and standardized scores. However, only a few tools have been available so far with limited usability. Here, we present siMacro, a fast and easy-to-use Microsoft Office Excel-based tool with a graphic user interface, designed to process single-condition or two-condition synthetic screen datasets. siMacro normalizes position and batch effects, censors outlier samples, and calculates Z-scores and robust Z-scores, with a spreadsheet output of >120,000 samples in under 1 minute.
High-Throughput Screening Assays
;
RNA Interference
;
RNA, Small Interfering
3.RNA interference (RNAi) as novel approach for gene silencing--review.
Journal of Experimental Hematology 2005;13(6):1141-1144
RNA interference (RNAi), a highly conserved evolutionary process of post-transcriptional gene silencing, can be triggered by small interfering RNAs (siRNAs) that mediate sequence-specific mRNA degradation. The article summarized some aspects of the mechanism of RNAi, siRNA design and delivery of siRNAs to mammalian somatic cells. And some hurdles in practice were also discussed.
Animals
;
Humans
;
RNA Interference
;
RNA, Small Interfering
;
genetics
;
Transfection
4.Construction of Dishevelled 2-targeted siRNA vectors and identification of the effective recombinant plasmids.
Juan ZHAO ; Xu HUANG ; Yingjie MAO
West China Journal of Stomatology 2011;29(5):529-533
OBJECTIVETo construct Dishevelled 2 (Dvl2)-targeted siRNA plasmids and to identify the effective recombinant plasmids in transciently-transfected RAW264.7 cells.
METHODSThe interfering sequences of Dvl2 were designed according to the sequence of Dvl2 of GenBank. Five paires of oligonucleotides were synthesized and inserted into plasmid pMAGic 4.0 to generate siRNA expression vectors, which were identified by flora PCR and sequence analysis. The recombinant plasmids siRNA-Dvl2 was transciently transfected into RAW264.7 cells by Lipofectamine 2000, which was confirmed under a fluorescence microscope and the interfering efficiency was detected by real-time RT-PCR.
RESULTSFive Dvl2 siRNA frames were successfully inserted into the plasmid vector pMAGic 4.0, and the flora PCR and sequence analysis confirmed the correct construction. Three of the five siRNA vectors suppressed the expression of Dvl2 mRNA, in which the siRNA-Dvl2-3 was the most efficient.
CONCLUSIONThe Dvl2-targeted recombinant siRNA plasmids can be constructed successfully to inhibit Dvl2 mRNA expression in transciently-transfected RAW264.7 cells, which can be used to pack virus particles and to construct siRNA-Dvl2 stably-transfected RAW264.7 cells in further research.
Genetic Vectors ; Humans ; Plasmids ; RNA, Messenger ; RNA, Small Interfering ; Transfection
5.Expression and roles of NUPR1 in cholangiocarcinoma cells.
Ki Sun KIM ; Du Il JIN ; Sik YOON ; Sun Yong BAEK ; Bong Seon KIM ; Sae Ock OH
Anatomy & Cell Biology 2012;45(1):17-25
Nuclear protein-1 (NUPR1) is a small nuclear protein that is responsive to various stress stimuli. Although NUPR1 has been associated with cancer development, its expression and roles in cholangiocarcinoma have not yet been described. In the present study, we found that NUPR1 was over-expressed in human cholangiocarcinoma tissues, using immunohistochemistry. The role of NUPR1 in cholangiocarcinoma was examined by its specific siRNA. NUPR1 siRNA decreased proliferation, migration and invasion of human cholangiocarcinoma cell lines (HuCCT1 and SNU1196 cells). From these results, we conclude that NUPR1 is over-expressed in cholangiocarcinoma and regulates the proliferation and motility of cancer cells.
Cell Line
;
Cholangiocarcinoma
;
Humans
;
Immunohistochemistry
;
Nuclear Proteins
;
RNA, Small Interfering
6.Transglutaminase 2 Promotes Autophagy by LC3 Induction through p53 Depletion in Cancer Cell.
Joon Hee KANG ; Seon Hyeong LEE ; Heesun CHEONG ; Chang Hoon LEE ; Soo Youl KIM
Biomolecules & Therapeutics 2019;27(1):34-40
Transglutaminase 2 (TGase 2) plays a key role in p53 regulation, depleting p53 tumor suppressor through autophagy in renal cell carcinoma. We found that microtubule-associated protein 1A/1B-light chain 3 (LC3), a hallmark of autophagy, were tightly associated with the level of TGase 2 in cancer cells. TGase 2 overexpression increased LC3 levels, and TGase 2 knockdown decreased LC3 levels in cancer cells. Transcript abundance of LC3 was inversely correlated with level of wild type p53. TGase 2 knockdown using siRNA, or TGase 2 inhibition using GK921 significantly reduced autophagy through reduction of LC3 transcription, which was followed by restoration of p53 levels in cancer cells. TGase 2 overexpression promoted the autophagy process by LC3 induction, which was correlated with p53 depletion in cancer cells. Rapamycin-resistant cancer cells also showed higher expression of LC3 compared to the rapamycin-sensitive cancer cells, which was tightly correlated with TGase 2 levels. TGase 2 knockdown or TGase 2 inhibition sensitized rapamycin-resistant cancer cells to drug treatment. In summary, TGase 2 induces drug resistance by potentiating autophagy through LC3 induction via p53 regulation in cancer.
Autophagy*
;
Carcinoma, Renal Cell
;
Drug Resistance
;
RNA, Small Interfering
7.Bis Is Involved in Glial Differentiation of P19 Cells Induced by Retinoic Acid.
Jung Sook YOON ; Mun Yong LEE ; Jae Seon LEE ; Chan Sun PARK ; Ho Joong YOUN ; Jeong Hwa LEE
The Korean Journal of Physiology and Pharmacology 2009;13(3):251-256
Previous observations suggest that Bis, a Bcl-2-binding protein, may play a role the neuronal and glial differentiation in vivo. To examine this further, we investigated Bis expression during the in vitro differentiation of P19 embryonic carcinoma cells induced by retinoic acid (RA). Western blotting and RT-PCR assays showed that Bis expression was temporarily decreased during the free floating stage and then began to increase on day 6 after the induction of differentiation. Double immunostaining indicated that Bis-expressing cells do not express several markers of differentiation, including NeuN, MAP-2 and Tuj-1. However, some of the Bis-expressing cells also were stained with GFAP-antibodies, indicating that Bis is involved glial differentiation. Using an shRNA strategy, we developed bis-knock down P19 cells and compared them with control P19 cells for the expression of NeuroD, Mash-1 and GFAP during RA-induced differentiation. Among these, only GFAP induction was significantly attenuated in P19-dnbis cells and the population showing GFAP immunoreactivity was also decreased. It is noteworthy that distribution of mature neurons and migrating neurons was disorganized, and the close association of migrating neuroblasts with astrocytes was not observed in P19-dnbis cells. These results suggest that Bis is involved in the migration-inducing activity of glial cells.
Astrocytes
;
Blotting, Western
;
Neuroglia
;
Neurons
;
RNA, Small Interfering
;
Tretinoin
8.Pathways and mechanisms of RNA interference mediated by viral siRNA.
Chinese Journal of Biotechnology 2021;37(4):1237-1248
RNA interference (RNAi) is one of the important mechanisms to regulate gene expression in eukaryotes. One of the original functions of RNAi is to facilitate the antiviral strategy of host. Early studies reveal that invertebrates can use RNAi to resist viruses. However, if this mechanism exists in mammals is still controversial. The latest studies confirm that mammals do have the RNAi-based immunity, and researchers believe that RNAi-based antiviral immunity is a brand-new immunological mechanism that was neglected in the past. It is worthy to note that virus can also use RNAi to enhance its infectivity and immune escape in host cells. This review introduces the research history of RNAi-based antiviral immunity in animals and summarizes the main findings in this field. Last but not least, we indicate a series of unresolved questions about RNAi-based antiviral immunity, and explore the relationship between RNAi-based antiviral immunity and other innate immunological pathways. The virus-mediated RNAi pathway in animal is not only an interesting basic biology question, but also has important guiding roles in the development of antiviral drugs.
Animals
;
Antiviral Agents
;
Immunity, Innate/genetics*
;
Mammals
;
RNA Interference
;
RNA, Small Interfering/genetics*
;
RNA, Viral
9.Regulation of non-coding RNA in type H vessels angiogenesis of bone.
Shengping TANG ; Shijie LIAO ; Jianhong LIU ; Xiaolin LUO ; Zhendi WEI ; Xiaofei DING
Chinese Journal of Reparative and Reconstructive Surgery 2023;37(8):1042-1048
OBJECTIVE:
To summarize the regulatory effect of non-coding RNA (ncRNA) on type H vessels angiogenesis of bone.
METHODS:
Recent domestic and foreign related literature about the regulation of ncRNA in type H vessels angiogenesis was widely reviewed and summarized.
RESULTS:
Type H vessels is a special subtype of bone vessels with the ability to couple bone formation. At present, the research on ncRNA regulating type H vessels angiogenesis in bone diseases mainly focuses on microRNA, long ncRNA, and small interfering RNA, which can affect the expressions of hypoxia inducible factor 1α, platelet derived growth factor BB, slit guidance ligand 3, and other factors through their own unique ways of action, thus regulating type H vessels angiogenesis and participating in the occurrence and development of bone diseases.
CONCLUSION
At present, the mechanism of ncRNA regulating bone type H vessels angiogenesis has been preliminarily explored. With the deepening of research, ncRNA is expected to be a new target for the diagnosis and treatment of vascular related bone diseases.
Humans
;
RNA, Untranslated/genetics*
;
RNA, Long Noncoding
;
Bone Diseases/genetics*
;
MicroRNAs/genetics*
;
RNA, Small Interfering
10.Recent advances on application of small RNA in research for hematological malignancies - review.
Journal of Experimental Hematology 2008;16(5):1237-1241
The small RNAs include siRNA and miRNA. SiRNA is the splicing product of exogenous dsRNA by which to keep genome stability, while miRNA are processed from endogenous genome and work as a post-transcriptional regulator for gene expression. The small RNAs act in two ways: mediate degradation of of target RNA and inhibit translation of protein. The former requires the accurate complementation between small RNA and target RNA, while the latter requires only partial complementation. Which mechanism used depends on complementation degree, but not their origins. The RNAi as a technique for down-regulating target gene expression has been widely used in functional genomic studies and hematologic studies, especially for translocation-related fusion gene, apoptosis-related gene and MDR gene in leukemia. The results show that RNAi technique not only is the powerful tool for study mechanism but also has therapeutic potentials in clinic. Some studies reveal that changes of miRNA expression exist in many hematological malignancies and relate to known oncogenes, which indicates the miRNA is involved in pathogenesis of these diseases. This article reviews the discovery and effect of RNAi and small RNAs, as well as the similarities and differences between siRNA and miRNA, and focuses on the research of small RNAs in hematological malignancies.
Hematologic Neoplasms
;
genetics
;
Humans
;
MicroRNAs
;
genetics
;
RNA
;
genetics
;
RNA Interference
;
RNA, Small Interfering
;
genetics